

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Policy Number	7.01.45
Category	Technology Assessment
Effective Date	10/18/01
Revised Date	02/21/02, 01/16/03, 11/20/03, 10/20/04, 08/18/05, 06/15/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10
Archived Date	05/19/11
Edited Date	05/24/12, 05/23/13, 05/22/14, 05/28/15, 05/25/16, 05/18/17, 05/17/18, 05/16/19, 03/19/20
Product Disclaimer	<ul style="list-style-type: none"> • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit. • If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

- I. Based upon our criteria and lack of peer-reviewed literature, *transesophageal radiofrequency* applications to the gastroesophageal junction (e.g., Stretta procedure) as a treatment of GERD has not been medically proven to be effective and, therefore, is considered **investigational**.
- II. Based upon our criteria and lack of peer-reviewed literature, *endoscopic gastroplasty/gastroplication* (e.g., EndoCinch, Sew- Right, Plicator™ System, Syntheon ARD Plicator) as a treatment of GERD has not been medically proven to be effective and, therefore, is considered **investigational**.
- III. Based upon our criteria and lack of peer-reviewed literature, *endoluminal fundoplication* (e.g., ELF, EsophyX™) or *transoral incisionless fundoplication* (TIF) as a treatment of GERD has not been medically proven to be effective and, therefore, is considered **investigational**.
- IV. Based upon our criteria and lack of peer-reviewed literature, injection/implantation of biocompatible material (e.g., endoscopic submucosal implantation of Plexiglas beads, Durasphere®, Enteryx or use of the Gatekeeper System) as a treatment of GERD has not been medically proven to be effective and, therefore, is considered **investigational**.

Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.

Refer to Corporate Medical Policy #7.01.89 Magnetic Esophageal Ring/Magnetic Sphincter Augmentation for the Treatment of Gastroesophageal Reflux Disease (GERD).

POLICY GUIDELINES

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and, thus, these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

GERD is defined as symptoms (e.g., heartburn, regurgitation, pain, and dysphagia) and/or tissue damage that results from the abnormal reflux of gastric contents into the esophagus and can significantly affect the quality of patients' lives. Initial

Medical Policy: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Policy Number: 7.01.45

Page: 2 of 6

treatment of GERD is geared toward reducing esophageal refluxes via medical therapies (dietary and lifestyle modifications, medications). When standard medical therapies fail, surgery may be considered. The quest for minimally invasive surgical techniques has led to the development of transendoscopic treatments for GERD. Endoscopic therapies can be classified into three categories: thermal methods, endoscopic suturing/stapling, and injection of implants made up of inert biocompatible material.

The *Stretta* procedure utilizes an endoscope and radiofrequency ablation to create thermal lesions in the submucosa of the gastroesophageal junction. Reduction in reflux is reported to occur due to heat-induced collagen retraction, delayed thermal resorption due to wound-healing, and afferent nerve pathway disruption at the gastroesophageal junction.

Endoscopic gastroplasty or *gastroplication* involves the suturing of the lower esophageal sphincter to strengthen and lengthen the sphincter in order to reduce reflux. Examples of gastroplication devices include the EndoCinch Suturing Device™, the Sew-Right Device®, the Syntheon ARD Plicator, and the NDO Plicator® System.

Another method of endoscopic treatment for GERD is the injection of inert, biocompatible material at or above the cardia. Polymethylmethacrylate (PMMA) or Plexiglas microspheres are injected into the lower esophageal folds. These microspheres, or beads, implant in the submucosa to augment the bulking of tissues and reduce reflux and symptoms of GERD. The Gatekeeper System uses the injection of a hydrogel prosthesis that, once expanded, allows augmentation of the lower esophageal sphincter (LES) by forming a soft, pliable lower-esophageal sphincter barrier. Enteryx, a polymer in the form of an injectable solution of ethylene vinyl alcohol that, when injected into the LES, solidifies into a spongy mass that forms a ring to reduce reflux, is no longer commercially available as treatment for GERD (see rationale statement). Pyrolytic carbon-coated beads (Durasphere®), FDA-approved as a submucosal urethral bulking agent, are being investigated in the treatment of mild-moderate GERD due to their success in the treatment of urinary incontinence resulting from intrinsic bladder deficiency. The beads are injected endoscopically in the region of the gastroesophageal junction (GEJ), with the intent to close/tighten the GEJ lumen.

Endoluminal fundoplication (ELF), also known as transesophageal (or transoral) incisionless fundoplication (TIF), is designed to restore the antireflux barrier by recreating the valve at the gastroesophageal junction. The fundoplication device is passed transorally under direct visualization by an endoscope. A proprietary esophageal invaginator incorporated into the device is used to engage the distal esophagus at the level of the Z-line, to reduce the hiatal hernia, if present. Gastric tissue from the fundus is then drawn between the body of the device and the tissue mold used to shape each portion of the gastroesophageal valve. Finally, several polypropylene fasteners are delivered across the mold tissue to create a three to five cm long serosa-to-serosa flap.

RATIONALE

The Bard Endocinch Suturing System™ received 510(k) premarket clearance from the FDA on March 20, 2000. The *Stretta*™ System received 510(k) premarket clearance from the FDA on April 18, 2000. Enteryx® received FDA clearance on April 22, 2003 for the treatment of patients with GERD who require and respond to proton pump inhibitors (PPIs). In October 2005, in a joint decision by the FDA and Boston Scientific, a voluntary recall was initiated of all Enteryx Procedure Kits and injector products from commercial distribution. This action was initiated by Boston Scientific based upon growing data evidence of serious adverse effects that occurred related to the incorrect transmural injection of the product into vital organs, which went unrecognized at the time of the procedure. On April 29, 2003, NDO Surgical announced that it had received clearance from the FDA for the Plicator device for the treatment of GERD. The Sew-Right Device®, the Syntheon ARD Plicator and Plexiglas beads currently does not have FDA approval for use in an anti-reflux application. The Gatekeeper System was actually withdrawn in late 2005, before FDA approval, and is not expected to be marketed.

The American College of Gastroenterology (ACOG) provided updated guidelines in January of 2005, identifying three broad categories of endoscopic therapy: radiofrequency application to the LES area, techniques designed to decrease reflux using endoscopic sewing devices, and techniques using an injection into the LES region. ACOG noted that all of these techniques seem to produce an improvement in reflux symptoms, although significant changes in lower esophageal sphincter pressure have not been demonstrated, and less than 35% of patients have been demonstrated to have

Medical Policy: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Policy Number: 7.01.45

Page: 3 of 6

normalization of their intraesophageal acid exposure (measured by pH testing). When results of the available studies are critically examined, many issues remain unresolved, including: long-term durability, safety and efficacy of these procedures performed outside of clinical trials, and efficacy in atypical presentations of GERD, among others. Systematic reviews were unable to identify any clear indications for these techniques, but did support their use in clinical trials and outside clinical trials in certain well-informed patients who have well-documented GERD that is responsive to PPI therapy.

EsophyX® (EndoGastric Solutions, Inc.), an endoluminal fundoplication device, received FDA clearance in September 2007. The 2006 Society of American Gastrointestinal Surgeons (SAGES) national meeting was the stage for several presentations describing ELF. The clinical data presented was from 17 GERD patients referred for laparoscopic surgery who were treated with an ELF procedure instead. GERD-HRQL scores at three months post-treatment improved 53%, and PPI use was eliminated in 15 of 17 subjects at a mean of 5.5 months after the intervention. Importantly, the investigators (Cadiere, Rajan) reported that the pH scores reflecting distal esophageal acid exposure normalized in 10 of 11 treated patients studied at three months. Adverse events included moderate throat irritation and epigastric pain, resolving within one week, with one admission for pain assessment with spontaneous resolution without determined cause. Further investigations are in progress; long-term outcomes data and a sham-controlled study are necessary to determine its efficacy and safety as a technique for the treatment of GERD. In 2016, the EsophyX® Z Device with SerosaFuse Fasteners was cleared for marketing by the FDA through the 510(k) process (K160960) for use in transoral tissue approximation, full-thickness plication, ligation in the gastrointestinal tract, narrowing the gastroesophageal junction, and reduction of hiatal hernias of two cm or less in patients with symptomatic chronic GERD. In June 2017, EsophyX2 HD and the third-generation EsophyX Z Devices with SerosaFuse fasteners and accessories were cleared for marketing by the FDA through the 510(k) process (K171307) for expanded indications, including patients who require and respond to pharmacologic therapy and patients with hiatal hernias larger than two cm when a laparoscopic hiatal hernia repair reduces a hernia to two cm or less.

Richter *et al.* (2018) performed a systematic review and network meta-analysis of randomized controlled trials completed as of May 10, 2017, to compare the relative efficacies of transoral incisionless fundoplication (TIF) versus laparoscopic nissen fundoplication (LNF) in patients with gastroesophageal reflux disease (GERD). The meta-analysis reviewed seven trials comprising 1,128 patients using Bayesian methods under random-effects, multiple-treatment comparisons. The comparative results from direct and network meta-analysis included the following results: TIF had the highest probability of increasing patients' health-related quality of life (0.96), followed by LNF (0.66), a sham procedure (0.35), and PPIs (0.042). LNF had the highest probability of increasing percent time at pH<4 (0.99), followed by PPIs (0.64), TIF (0.32), and the sham procedure (0.05). LNF also had the highest probability of increasing LES pressure (0.78), followed by TIF (0.72) and PPIs (0.01). Patients who underwent the sham procedure had the highest probability for persistent esophagitis (0.74), followed by those receiving TIF (0.69), LNF (0.38), and PPIs (0.19). The meta-analysis did not review adverse effects/harm, as it was not reported consistently across all of the studies. The authors concluded that LNF is superior to TIF and PPIs for improving physiologic parameters of chronic GERD, including increased LES pressure and decreased percent time pH. TIF was not recommend as a long-term alternative to PPI or LNF treatment of GERD, as long-term efficacy has not been demonstrated.

Ongoing clinical trials and studies of transesophageal endoscopic therapies for the treatment of gastroesophageal reflux disease (GERD) continue to be conducted, which include transesophageal (or transoral) incisionless fundoplication (TIF), application of radiofrequency energy, and injection/implantation of prosthetic devices or bulking agents. Large-scale, long-term, controlled studies of these three transendoscopic techniques are needed, to establish the safety and efficacy of these procedures.

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- ***CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.***

Medical Policy: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Policy Number: 7.01.45

Page: 4 of 6

- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT Codes

Code	Description
43192 (E/I)	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
43201 (E/I)	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43210 (E/I)	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed
43236 (E/I)	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43257 (E/I)	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease

Copyright © 2020 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
none	

ICD10 Codes

Code	Description
K21.0	Gastro-esophageal reflux disease with esophagitis
K21.9	Gastro-esophageal reflux disease without esophagitis

REFERENCES

*Abou-Rebyeh H, et al. Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. Endoscopy 2005 Mar;37(3):213-6.

American College Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2013 Mar [<http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/>] accessed 1/20/20.

American Gastroenterological Association. AGA Institute medical position statement on the management of gastroesophageal reflux disease. 2008 [[https://www.gastrojournal.org/article/S0016-5085\(08\)01606-5/pdf](https://www.gastrojournal.org/article/S0016-5085(08)01606-5/pdf)] accessed 1/20/20.

*Arts J, et al. A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci 2005 Feb;50(2):351-6.

BlueCross BlueShield Association. Transendoscopic therapies for gastroesophageal reflux disease. Medical Policy Reference Manual Policy #2.01.38. 2019 Nov 14.

*BlueCross BlueShield Association Technology Evaluation Center (TEC). Transesophageal endoscopic treatments for gastroesophageal reflux disease. 2004 Feb;18(20).

*Cadiere GB, et al. Endoluminal fundoplication (ELF)- evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 2006 Dec;15(6):348-55.

*Cadiere GB, et al. Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility study. Surg Endosc 2008 Feb;22(2):333-42.

Medical Policy: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Policy Number: 7.01.45

Page: 5 of 6

*Cadiere GB, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12 month results of a prospective multicenter study. World J Surg 2008 Aug;32(8):1676-88.

*Cadiere GB, et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 2009 May;23(5):957-964.

Chimukangara M, et al. Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study. Surg Endosc 2019 Apr;33(4):1304–1309.

*Cipolletta L, et al. Delivery of radiofrequency energy to the gastroesophageal junction (Stretta procedure) for the treatment of gastroesophageal reflux disease. Surg Endosc 2005 May 3.

*Cohen LB, et al. Enteryx implantation for GERD: expanded multicenter trial results and interim post approval follow-up to 24 months. Gastrointest Endosc 2005 May;61(6):650-8.

*DeVault KR, American College of gastroenterology, et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan;100(1):190-200.

*Deviere J, et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterol 2005 Mar;128(3):532-40.

Fass R, et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc 2017 Dec;31(12):4865-4882.

Janu P, et al. Laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication with EsophyX device (HH + TIF): efficacy and safety in two community hospitals. Surg Innov 2019 Dec; 26(6):675–686.

*Lehman G. Endoscopic and endoluminal techniques for control of gastroesophageal reflux: are they ready for widespread clinical applications?. Gastrointest Endosc 2000 Dec;52(6)Pt 1:808-11.

*Lufti RE, et al. Three year's experiences with the Stretta procedure: did it really make a difference? Surg Endosc 2005 Feb;19(2):289-95.

McCarty TR, et al. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy 2018 Jul;50(7):708-725.

National Institute for Health and Clinical Excellence (NICE). Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. IPG461. 2013 Aug [<https://www.nice.org.uk/guidance/ipg461>] accessed 1/20/20.

*Pleskow D, et al. Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc 2005 May;61(6):643-9.

Richter JE, et al. Efficacy of laparoscopic nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. Gastroenterology 2018 Apr;154(5):1298-1308.

*Schiefke I, et al. Long-term failure of endoscopic gastroplication (EndoCinch). Gut 2005 Jun;54(6):752-8.

*Schiefke I, et al. Use of an endoscopic suturing device (the “ESD”) to treat patients with gastroesophageal reflux disease, after unsuccessful EndoCinch endoluminal gastroplication: another failure. Endoscopy 2005 Aug;37(8):700-5.

Testoni PA, et al. Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years. Endoscopy International Open 2019; 07: E647–E654.

*Torquati A, et al. Long-term follow-up study of the Stretta procedure for the treatment of gastroesophageal reflux disease. Surg Endosc 2004 Oct;18(10):1475-9.

Trad KS, et al. The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surgical Innovation 2018; Vol. 25(2) 149–157.

Medical Policy: TRANSENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Policy Number: 7.01.45

Page: 6 of 6

*Triadafilopoulous G, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc 2001 Apr;53(4):407-15.

*Triadafilopoulous G, et al. The Stretta procedure for the treatment of GERD 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc 2002 Feb;55(2):149-56.

U.S. Department of Health and Human Services Agency for Health Research and Quality. Comparative effectiveness of management strategies for gastroesophageal reflux disease – an update to the 2005 report.

[<https://effectivehealthcare.ahrq.gov/topics/gerd/research>] accessed 1/20/20.

*Watson TJ, et al. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease. Thorac Surg Clin 2005 Aug;15(3):405-15.

*Wolfsen HC, et al. The Stretta procedure for the treatment of GERD: a registry of 558 patients. J Laparosc Adv Surg Tech A 2002 Dec;12(6):395-402.

*Key Article

KEY WORDS

ELF, Endocinch, endoluminal fundoplication, Enteryx, EsophyX, Gastroplication, Gatekeeper, NDO Plicator System, Stretta.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) for the endoscopic treatment of GERD. Please refer to the following LCD website for Medicare Members:

[https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35080&ver=42&CntrctrSelected=298*1&Cntrctr=298&name=National+Government+Services%2c+Inc.+\(13201%2c+A+and+B+and+HHH+MAC%2c+J+K\)&s=All&DocType=Active&bc=AggAAAQBAAAA&](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35080&ver=42&CntrctrSelected=298*1&Cntrctr=298&name=National+Government+Services%2c+Inc.+(13201%2c+A+and+B+and+HHH+MAC%2c+J+K)&s=All&DocType=Active&bc=AggAAAQBAAAA&)